BioSpace News Archive

Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the H.C. Wainwright 24th Annual Global Investment Conference.

Mydecine Innovations Group Inc. announced that it has entered into a Common Share Subscription Agreement with a third-party investor in the Company.

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 – September 2.

Haemonetics Corporation announced an agreement with Epic, a leading Electronic Health Record system, to offer Haemonetics’ SafeTrace Tx® blood bank information system to Epic’s global network of hospitals.

Conformis, Inc. announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today provided a corporate update and reported financial results for the first half of 2022.

Clover Biopharmaceuticals, Ltd. announced positive Phase 2/3 clinical trial data demonstrating that its lead COVID-19 vaccine candidate, SCB-2019, elicited a robust immune response to Omicron BA.5 subvariant, the dominant SARS-CoV-2 variant circulating globally, building upon previously announced results for neutralization against Omicron BA.2 and BA.1.

Atmofizer Technologies Inc. (the “Company” or “Atmofizer”) (CSE: ATMO) (Frankfurt: J3K) (OTCQB: ATMFF) is pleased to announce its financial results for the quarter ended June 30, 2022.

Baudax Bio, Inc. announced the pricing of its public offering of an aggregate of 11,819,172 shares of its common stock, together with accompanying common stock purchase warrants, at a public offering price of $0.525 per share and accompanying warrants.

The global pharmaceutical excipients market was valued at US$ 6.9 Bn in 2018 and is projected to expand at a high CAGR from 2019 to 2027.